Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab in PED Secondary to AMD
NCT00976222Phase 4Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Dec 2008
- Primary completion
- Dec 2014
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of ranibizumab in retinal pigment epithelial detachment (PED), sponsored by Universitätsklinikum Münster. Started Dec 2008; status: completed.
02
Drugs
ranibizumab
03
Conditions
retinal pigment epithelial detachment (PED)
Beyond the preview
Go deeper on NCT00976222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00976222.